Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
DB19221InvestigationalSmall molecule
2-(1-(1-(2-chlorophenyl)-2-methoxy-2-oxoethyl)-4-sulfanyl-3-piperidinylidene) acetic acid is under investigation in clinical trial NCT03774394 (Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus).
- Formula / weight
- C16H18ClNO4S · 355.83 g/mol (avg)
- Also known as
- 1-piperidineacetic acid, 3-(carboxymethylene)-.alpha.-(2-chlorophenyl)-4-mercapto-, 1-methyl ester, (.alpha.s,3z)- · 3-(carboxymethylene)-.alpha.-(2-chlorophenyl)-4-mercapto-1-piperidineacetic acid 1-methyl ester, (.alpha.s,3z)- · Clopidogrel active metabolite
Resolves to
Compound
Structure
InChIKey
CWUDNVCEAAXNQA-AWGNNQSZSA-NSMILESCOC(=O)[C@@H](N1CCC(S)\C(C1)=C/C(O)=O)C1=CC=CC=C1ClWhat you can answer from here — as of April 02, 2025
Which companies are running trials of 2-(1-(1-(2-chlorophenyl)-2-methoxy-2-oxoethyl)-4-sulfanyl-3-piperidinylidene) acetic acid, in which indications and phases, and which of those programs are still active?